药品名称 | ABILIFY | 申请号 | 021729 | 产品号 | 005 | 活性成分 | ARIPIPRAZOLE | 市场状态 | 停止上市 | 剂型或给药途径 | TABLET, ORALLY DISINTEGRATING;ORAL | 规格 | 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | 治疗等效代码 | | 参比药物 | 否 | 批准日期 | 2006/06/07 | 申请机构 | OTSUKA PHARMACEUTICAL CO LTD
| 化学类型 | New dosage form | 审评分类 | Standard review drug |
|
|
|
|
与药品注册相关的信息 | 申请号 | 修订号 | 审批结论 | 公开文档类型 | 文档创建时间 | 获取文档 | 021729 | 024 | AP | Letter | 2016/08/19 | 下载 | 021729 | 024 | AP | Label | 2016/08/23 | 下载 | 021729 | 023 | AP | Letter | 2016/01/20 | 下载 | 021729 | 023 | AP | Label | 2016/01/22 | 下载 | 021729 | 022 | AP | Letter | 2014/12/15 | 下载 | 021729 | 022 | AP | Label | 2014/12/15 | 下载 | 021729 | 021 | AP | Letter | 2013/08/05 | 下载 | 021729 | 021 | AP | Label | 2013/08/09 | 下载 | 021729 | 020 | AP | Label | 2014/06/10 | 下载 | 021729 | 020 | AP | Letter | 2014/07/11 | 下载 | 021729 | 018 | AP | Label | 2012/02/24 | 下载 | 021729 | 018 | AP | Letter | 2012/02/27 | 下载 | 021729 | 017 | AP | Label | 2011/03/07 | 下载 | 021729 | 017 | AP | Letter | 2011/03/08 | 下载 | 021729 | 016 | AP | Label | 2010/12/03 | 下载 | 021729 | 016 | AP | Letter | 2010/12/07 | 下载 | 021729 | 015 | AP | Letter | 2010/12/03 | 下载 | 021729 | 015 | AP | Label | 2010/12/02 | 下载 | 021729 | 014 | AP | Letter | 2011/02/18 | 下载 | 021729 | 014 | AP | Label | 2011/02/24 | 下载 | 021729 | 013 | AP | Label | 2009/07/23 | 下载 | 021729 | 013 | AP | Letter | 2009/07/24 | 下载 | 021729 | 012 | AP | Letter | 2008/08/19 | 下载 | 021729 | 012 | AP | Label | 2008/08/26 | 下载 | 021729 | 010 | AP | Letter | 2008/03/07 | 下载 | 021729 | 009 | AP | Letter | 2008/05/14 | 下载 | 021729 | 009 | AP | Summary Review | 2008/07/17 | 下载 | 021729 | 009 | AP | Review | 2012/01/27 | 下载 | 021729 | 008 | AP | Label | 2008/02/28 | 下载 | 021729 | 008 | AP | Letter | 2008/02/29 | 下载 | 021729 | 007 | AP | Letter | 2008/05/14 | 下载 | 021729 | 007 | AP | Summary Review | 2008/07/17 | 下载 | 021729 | 007 | AP | Review | 2012/01/27 | 下载 | 021729 | 006 | AP | Review | 2012/01/27 | 下载 | 021729 | 006 | AP | Summary Review | 2008/07/17 | 下载 | 021729 | 006 | AP | Letter | 2008/05/14 | 下载 | 021729 | 005 | AP | Label | 2007/11/19 | 下载 | 021729 | 005 | AP | Letter | 2007/11/19 | 下载 | 021729 | 004 | AP | Label | 2007/11/07 | 下载 | 021729 | 004 | AP | Letter | 2007/11/08 | 下载 | 021729 | 002 | AP | Label | 2007/09/26 | 下载 | 021729 | 002 | AP | Letter | 2007/10/04 | 下载 | 021729 | 001 | AP | Label | 2006/10/23 | 下载 | 021729 | 001 | AP | Letter | 2006/10/23 | 下载 | 021729 | 000 | AP | Review | 2007/08/31 | 下载 | 021729 | 000 | AP | Label | 2006/06/08 | 下载 | 021729 | 000 | AP | Letter | 2006/06/12 | 下载 | 021729 | 000 | AP | Other Important Information from FDA | 2011/12/22 | 下载 | 021729 | 000 | AP | Medication Guide | 2010/02/17 | 下载 |
|
药品注册审批历史信息 | 申请号 | 修订号 | 审批结论 | 审批日期 | 审批内容 | 021729 | 024 | AP | 2016/08/18 | Labeling Revision | 021729 | 023 | AP | 2016/01/15 | Labeling Revision | 021729 | 022 | AP | 2014/12/12 | Efficacy Supplement with Clinical Data to Support | 021729 | 021 | AP | 2013/07/30 | Labeling Revision | 021729 | 020 | AP | 2014/06/09 | Labeling Revision | 021729 | 018 | AP | 2012/02/22 | Labeling Revision | 021729 | 017 | AP | 2011/03/02 | Labeling Revision | 021729 | 016 | AP | 2010/12/01 | Labeling Revision | 021729 | 015 | AP | 2010/11/30 | Labeling Revision | 021729 | 014 | AP | 2011/02/16 | Efficacy Supplement with Clinical Data to Support | 021729 | 013 | AP | 2009/07/19 | Labeling Revision | 021729 | 012 | AP | 2008/08/14 | Labeling Revision | 021729 | 010 | AP | 2008/03/06 | Labeling Revision | 021729 | 009 | AP | 2008/05/06 | Labeling Revision | 021729 | 008 | AP | 2008/02/27 | Patient Population Altered | 021729 | 007 | AP | 2008/05/06 | New or Modified Indication | 021729 | 006 | AP | 2008/05/06 | New Dosage Regimen | 021729 | 005 | AP | 2007/11/16 | New or Modified Indication | 021729 | 004 | AP | 2007/10/29 | Patient Population Altered | 021729 | 002 | AP | 2007/09/25 | Labeling Revision | 021729 | 001 | AP | 2006/10/20 | Labeling Revision | 021729 | 000 | AP | 2006/06/07 | Approval |
|